Company Profile

Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health and endocrine diseases. Our experienced team is dedicated to developing innovative therapies in areas of high unmet medical need to improve the lives of the millions of patients suffering from endocrine-related disorders such as uterine fibroids, endometriosis and prostate cancer.

Our lead program is relugolix, a once-daily, orally administered, small molecule investigational drug candidate that has the potential to be best-in-class for the treatment of uterine fibroids and endometriosis, and a potential best- and first-in-class treatment for advanced prostate cancer. To date, relugolix has been evaluated in over 1,300 patients. Results so far from large, randomized Phase 2 clinical trials in patients with uterine fibroids, endometriosis and prostate cancer have successfully demonstrated significant clinical benefit and that relugolix was generally well-tolerated.

In addition, we are developing MVT-602, an oligopeptide kisspeptin analog, for the treatment of female infertility. We believe it has the potential to be a safer alternative to human chorionic gonadotropin as part of assisted reproduction.

Over time, we intend to expand our development pipeline to include other potential treatments for endocrine-related disorders.